FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Carr Pa	(Fi WATERLO LOO RD	3. D 08/	Issuer Name and Ticker or Trading Symbol     Jazz Pharmaceuticals plc [ JAZZ ]      Date of Earliest Transaction (Month/Day/Year)     08/15/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)									S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director							
(City)	(St		(Zip)																
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)					ction	tion 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)					or and 5) 5. Amount of Securities Beneficially Owned Follow		nt of es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Pri	ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Ordinary Shares 08/13						2022		<b>S</b> <sup>(1)</sup>		142	142 D		156.86	5,934			D		
Ordinary Shares 08/15/2						2022		M		2,000	2,000 A \$		113.1	1 7,934		D			
Ordinary Shares 08/15/2					/2022	2022		S		2,000	D	\$1	160.29	5,934			D		
		Т	able II -								osed of, converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transaction Code (Instr. 8)		n of		6. Date E Expiration (Month/E	n Dat		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		S (I	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or	ount nber res					
Non- Qualified Stock Option (right to	\$113.1	08/15/2022			М			2,000	(2)		02/26/2030	Ordinary Shares	2,0	000	\$0.0	4,500		D	

## **Explanation of Responses:**

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

By: /s/Adam Guttmann, as attorney in fact For: Patricia

08/17/2022

Carr

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.